Total Payments
$293,446
2024 Payments
$94,149
Companies
52
Transactions
830
Medicare Patients
5,435
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$186,201 (63.5%)
Consulting$51,794 (17.7%)
Travel$38,179 (13.0%)
Food & Beverage$17,217 (5.9%)
Education$55.31 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $149,303 | 83 | 50.9% |
| Consulting Fee | $51,794 | 20 | 17.7% |
| Travel and Lodging | $38,179 | 140 | 13.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $25,848 | 22 | 8.8% |
| Food and Beverage | $17,217 | 558 | 5.9% |
| Honoraria | $11,050 | 5 | 3.8% |
| Education | $55.31 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $81,936 | 112 | $0 (2024) |
| Allergan, Inc. | $55,110 | 126 | $0 (2022) |
| Corium, LLC | $42,304 | 66 | $0 (2023) |
| Alnylam Pharmaceuticals Inc. | $27,853 | 41 | $0 (2024) |
| Biogen, Inc. | $19,734 | 28 | $0 (2024) |
| Lilly USA, LLC | $18,139 | 57 | $0 (2024) |
| Akcea Therapeutics, Inc. | $13,866 | 16 | $0 (2019) |
| Avanir Pharmaceuticals, Inc. | $9,215 | 15 | $0 (2018) |
| Otsuka America Pharmaceutical, Inc. | $6,399 | 10 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $5,022 | 9 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $94,149 | 234 | Eisai Inc. ($49,143) |
| 2023 | $72,744 | 210 | Eisai Inc. ($32,534) |
| 2022 | $39,092 | 113 | Biogen, Inc. ($19,342) |
| 2021 | $2,182 | 67 | Dr.Reddy's Laboratories,Inc. ($799.00) |
| 2020 | $343.95 | 17 | Allergan, Inc. ($52.76) |
| 2019 | $14,653 | 45 | Akcea Therapeutics, Inc. ($13,866) |
| 2018 | $6,454 | 21 | Avanir Pharmaceuticals, Inc. ($6,115) |
| 2017 | $63,828 | 123 | Allergan Inc. ($54,646) |
All Payment Transactions
830 individual payment records from CMS Open Payments — Page 1 of 34
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Abbott Laboratories | ETERNA (Device) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Neuromodulation | ||||||
| 12/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Neuroscience | ||||||
| 12/19/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $29.00 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/18/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $34.09 | General |
| Category: Neurology | ||||||
| 12/07/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: Musculoskeletal | ||||||
| 12/06/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $31.10 | General |
| Category: Neuroscience | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,280.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | REVANCE THERAPEUTICS, INC. | DAXXIFY (Drug) | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: AESTHETICS AND THERAPEUTICS | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $32.33 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/23/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $34.00 | General |
| Category: Neurology | ||||||
| 11/22/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: PAIN | ||||||
| 11/20/2024 | Eisai Inc. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 11/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | ABBVIE INC. | BOTOX (Biological), QULIPTA | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $18.00 | General |
| Category: Neuroscience | ||||||
| 11/20/2024 | Lilly USA, LLC | KISUNLA (Drug) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Neuroscience | ||||||
| 11/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: Neurology | ||||||
| 11/18/2024 | ARGENX US, INC. | VYVGART HYTRULO (Drug) | Food and Beverage | In-kind items and services | $1.29 | General |
| Category: Neurology | ||||||
| 11/15/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Neuroscience | ||||||
| 11/15/2024 | Lilly USA, LLC | KISUNLA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Neuroscience | ||||||
| 11/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,280.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | Cash or cash equivalent | $98.67 | General |
| Category: Neuroscience | ||||||
| 11/11/2024 | Merz Pharmaceuticals, LLC | Xeomin (Biological) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: Musculoskeletal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,552 | 14,024 | $2.0M | $358,969 |
| 2022 | 17 | 1,515 | 10,095 | $1.8M | $326,910 |
| 2021 | 18 | 1,199 | 8,885 | $1.4M | $277,532 |
| 2020 | 18 | 1,169 | 9,773 | $1.4M | $272,300 |
Total Patients
5,435
Total Services
42,777
Medicare Billing
$1.2M
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 281 | 631 | $497,060 | $85,340 | 17.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 29 | 11,600 | $278,400 | $57,439 | 20.6% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 140 | 141 | $269,874 | $51,505 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 219 | 624 | $350,688 | $49,507 | 14.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 125 | 125 | $122,000 | $21,823 | 17.9% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 76 | 76 | $77,596 | $17,469 | 22.5% |
| 95925 | Placement of skin electrodes and measurement of stimulated sites in arms | Office | 2023 | 100 | 102 | $74,460 | $15,243 | 20.5% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 47 | 48 | $53,568 | $9,923 | 18.5% |
| 92653 | Evaluation of brain response to sound for diagnosis of nervous system disorders with interpretation and report | Office | 2023 | 137 | 138 | $50,508 | $9,821 | 19.4% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 55 | 115 | $50,491 | $9,338 | 18.5% |
| 95930 | Measurement of nerve conduction using visual stimulation testing with report | Office | 2023 | 139 | 140 | $39,900 | $7,717 | 19.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 18 | 36 | $27,792 | $5,486 | 19.7% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Office | 2023 | 52 | 52 | $57,928 | $5,346 | 9.2% |
| 95926 | Placement of skin electrodes and measurement of stimulated sites in legs | Office | 2023 | 36 | 36 | $22,140 | $4,676 | 21.1% |
| 76882 | Limited ultrasound scan of joint or other extremity structure except blood vessels | Office | 2023 | 53 | 107 | $25,787 | $3,884 | 15.1% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 11 | 19 | $23,180 | $3,797 | 16.4% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 34 | 34 | $2,618 | $656.20 | 25.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 263 | 557 | $438,916 | $80,214 | 18.3% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 141 | 142 | $271,788 | $52,957 | 19.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 550 | $309,100 | $44,523 | 14.4% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 19 | 7,800 | $187,200 | $38,021 | 20.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 126 | 126 | $122,976 | $23,223 | 18.9% |
| 95925 | Placement of skin electrodes and measurement of stimulated sites in arms | Office | 2022 | 83 | 84 | $61,320 | $13,236 | 21.6% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 47 | 47 | $49,061 | $11,224 | 22.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2022 | 61 | 128 | $55,424 | $10,906 | 19.7% |
About Dr. Jeffrey Gelblum, MD
Dr. Jeffrey Gelblum, MD is a Neurology healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124057898.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Gelblum, MD has received a total of $293,446 in payments from pharmaceutical and medical device companies, with $94,149 received in 2024. These payments were reported across 830 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($149,303).
As a Medicare-enrolled provider, Gelblum has provided services to 5,435 Medicare beneficiaries, totaling 42,777 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Aventura, FL
- Active Since 07/03/2006
- Last Updated 10/11/2024
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1124057898
Products in Payments
- Leqembi (Drug) $71,251
- NAMZARIC (Drug) $54,623
- Adlarity (Drug) $27,495
- AMVUTTRA (Drug) $21,885
- KISUNLA (Drug) $15,802
- TEGSEDI (Drug) $13,866
- ADLARITY (Drug) $13,099
- ADUHELM (Biological) $10,873
- ONZETRA Xsail (Drug) $9,209
- REXULTI (Drug) $6,399
- ONPATTRO (Drug) $5,968
- NUPLAZID (Drug) $5,022
- WAINUA (Drug) $2,785
- AZSTARYS (Drug) $1,462
- BOTOX (Biological) $955.98
- UBRELVY (Drug) $597.55
- EMGALITY (Drug) $462.48
- INFINITY (Device) $421.26
- QULIPTA (Drug) $375.09
- INGREZZA (Drug) $344.95
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Aventura
Jonathan Cross, Md, MD
Neurology — Payments: $21,141
Neurology $21,141
Dr. Luis Becerra-Cabal, M.d, M.D
Neurology — Payments: $19,395
Neurology $19,395
Dr. Raul Grosz, Md, MD
Neurology — Payments: $9,540
Neurology $9,540
Dr. Michael Crimmins, Md, MD
Neurology — Payments: $3,424
Neurology $3,424
Theodore Wein, Md, MD
Neurology — Payments: $549.40
Neurology $549.40
Dr. Sheryl Strasser, Md, MD
Neurology — Payments: $288.74
Neurology $288.74